公开(公告)号：US20220267348A1

公开(公告)日：2022-08-25

申请号：US17628976

申请日：2020-07-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Saleem Ahmad ,  Ling Li ,  Hong Wu ,  John Hynes

IPC: C07D495/04 ,  C07D513/04

Abstract: Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or a salt or prodrug thereof, wherein: X is CR4 or N; and R1, R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

公开(公告)号：US20210147361A1

公开(公告)日：2021-05-20

申请号：US16636662

申请日：2018-08-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Ling Li ,  T.G. Murali Dhar ,  Hai-Yun Xiao

IPC: C07D213/53 ,  C07D207/12 ,  C07D211/40 ,  C07D211/96 ,  A61P37/06

Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L1 is —CR3═N—O—CRaRa— or CRaR—O—N═CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20210147357A1

公开(公告)日：2021-05-20

申请号：US16636670

申请日：2018-08-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Ling Li ,  John L. Gilmore

IPC: C07D207/16

Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is —CH2— or —C(O)—; R1 is —OH or —OP(O)(OH)2; L is a bond, —CH2—, or —C(O)—; R2 is n-C6-8 alkyl; each R3 is independently selected from Cl and —CH3; and n is zero, 1, or 2; provided that if X is —CH2—, then L is —CH2— or —C(O)—. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor SlP1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20170283463A1

公开(公告)日：2017-10-05

申请号：US15475227

申请日：2017-03-31

Applicant: Bristol-Myers Squibb Company

Inventor： Michael Matthew Miller ,  Martin Patrick Allen ,  Ling Li ,  Michael S. Bowsher ,  Eric P. Gillis ,  Eric Mull ,  Qian Zhao ,  Li-Qiang Sun ,  David R. Langley ,  Paul Michael Scola

IPC: C07K7/56

CPC classification number: C07K7/56 ,  A61K38/00 ,  A61K38/12 ,  C07K7/08 ,  C07K7/54 ,  C07K7/64 ,  Y02A50/463

Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.